Clinical Trials

The clinical trials listed below are for informational purposes only and are not endorsed by the AST. More information on clinical trials can be found in our clinical trials brochure. For information about posting a clinical trial, contact JoAnn Gwynn at jgwynn@myast.org.

Clinical Trials for Kidney Recipients

• Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 3-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred ALVR105 (Viralym-M) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia
  Sponsor: Allovir
  Organ Type: All organs
  Ages Accepted: 18+
  Genders Accepted: Both male and female
  Expected Study Completion Date:  Saturday, March 30, 2024
  Other Requirements
   
• Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA)
  Sponsor: AstraZeneca
  Organ Type: All organs
  Genders Accepted: Both male and female
  Expected Study Completion Date:   Tuesday, January 21, 2025
  Other Requirements
   
• Tabelecleucel for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
  Sponsor: Atara Biotherapeutics
  Organ Type: All organs
  Ages Accepted: All ages
  Genders Accepted: Both male and female
  Expected Study Completion Date: Wednesday, June 30, 2027
  Other Requirements
   
• An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases (EBVision)
  Sponsor: Atara Biotherapeutics
  Organ Type: All organs
  Ages Accepted: All ages
  Genders Accepted: Both male and female
  Expected Study Completion Date:  Wednesday, June 30, 2027
  Please refer to https://clinicaltrials.gov/study/NCT04554914 as this is a multi-cohort study which includes options for EBV+ PTLD where standard first-line therapy is inappropriate.
   
• Interleukin 6 blockade Modifying Antibody mediated Graft INjury and eGFR decline (IMAGINE)
  Sponsor: CSL Behring
  Organ Type: Kidney
  Ages Accepted: 18 years old to 70 years old
  Genders Accepted: Both male and female
  Expected Study Completion Date: April 2028
  Other Requirements
   
• Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx (ConfIdeS)
  Sponsor: Hansa Biopharma
  Organ Type: Kidney
  Ages Accepted: ≥18 and ≤70 years
  Genders Accepted: Both male and female
  Expected Study Completion Date:  December 31, 2023 
  Other Requirements
   
• SAFE KIDNEY II
  Sponsor: Memo Therapeutics
  Organ Type: Kidney
  Ages Accepted: 18+
  Genders Accepted: Both male and female
  Expected Study Completion Date:  November 24, 2024
  Other Requirements
   
• A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)
  Sponsor: Novartis 
  Organ Type: Kidney
  Ages Accepted: 18+
  Genders Accepted: Both male and female
  Expected Study Completion Date: July 28, 2026
  Other Requirements
   

Clinical Trials for Other Organ Types

• Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 3-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred ALVR105 (Viralym-M) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia
  Sponsor: Allovir
  Organ Type: All organs
  Ages Accepted: 18+
  Genders Accepted: Both male and female
  Expected Study Completion Date:  Saturday, March 30, 2024
  Other Requirements
   
• Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA)
  Sponsor: AstraZeneca
  Organ Type: All organs
  Genders Accepted: Both male and female
  Expected Study Completion Date:   Tuesday, January 21, 2025
  Other Requirements
   
• Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
  Sponsor: Atara Biotherapeutics
  Organ Type: All organs
  Ages Accepted: All ages
  Genders Accepted: Both male and female
  Expected Study Completion Date: Wednesday, June 30, 2027
  Other Requirements
   
• An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases (EBVision)
  Sponsor: Atara Biotherapeutics
  Organ Type: All organs
  Ages Accepted: All ages
  Genders Accepted: Both male and female
  Expected Study Completion Date:  Wednesday, June 30, 2027
  Please refer to https://clinicaltrials.gov/study/NCT04554914 as this is a multi-cohort study which includes options for EBV+ PTLD where standard first-line therapy is inappropriate.
   
• A 12-month, Open-label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of an Anti-CD40 Monoclonal Antibody, CFZ533 vs. Standard of Care Control, in Adult de Novo Liver Transplant Recipients With a 12-month Additional Follow-up (CONTRAIL I)
  Sponsor: Novartis 
  Organ Type: Liver
  Ages Accepted: 18 years to 70 years 
  Genders Accepted: Both male and female
  Expected Study Completion Date: April 26, 2023
  Other Requirements